Source reading · Omnivore, Ankur Capital, Kalaari, Speciale Invest

Several India deeptech investors point to the step after the lab.

A source-by-source reading of 43 entries from 9 publications by four India-focused investors, across agriculture, biology, materials, water, health records and earth observation.

Every publication stays its own collection with its own link and recorded date. These are investor publications, and most describe companies the investor has backed. Portfolio companies and investment rationales are treated as examples of an approach, never as proof of unmet demand. Kalaari's two collections come from public summary pages only; the full reports were not reviewed.

In each collection, “The source” describes what the publication is and what was reviewed. “Our reading” and the patterns across collections are Bharat in Beta's interpretation. No source text, figures or images are reproduced; follow the links for the original framing.

Nine collections, read one at a time

Omnivore, Harvest 37

The source. A fund newsletter that reports on Omnivore’s own portfolio companies and announces a separate study of agritech in Southeast Asia. Five entries are portfolio companies named as examples. Four are verticals from the study, which is a separate document and was not reviewed. Read the original (Published: 17 Jun 2026).Our reading. The portfolio examples share a pattern: each pairs a biological or agricultural input with an established industry such as textiles, animal feed, confectionery or carbon markets. The work that decides success sits in supply, verification and getting an incumbent buyer to change an input. These are companies already doing the work, so they show approaches, not open space.Browse this collection in the Atlas

Industrial-partner carbon removal Integrated premium cacao brands Agricultural-fibre textile innovation Insect-derived animal feed ingredients Biological crop stimulants Southeast Asian digital agricultural value chains (source only)Inclusive agricultural financial services (source only)Agrifood life-science businesses (source only)Sustainable consumer brands in Southeast Asia (source only)

Ankur Capital, India's BioEconomy Roadmap 2035 commentary

The source. Ankur Capital’s commentary on a government roadmap for India’s bioeconomy. Each entry corresponds to a mission or theme the commentary describes. Only the commentary was reviewed, not the roadmap itself. Read the original (Published: 28 Aug 2026).Our reading. The missions read as policy priorities, and policy attention is not the same as a buyer. The most specific constraint the commentary names is the move from laboratory to commercial production, which is why the scale-up entry is the one that most clearly suggests a service other ventures would need.Browse this collection in the Atlas

Accessible gene therapies and precision diagnostics Biological agricultural inputs Next-generation biologics platforms Marine biomaterials and ingredients Biomanufacturing scale-up infrastructure Integrated biosurveillance infrastructure (source only)

Ankur Capital, IBISA investment rationale

The source. Ankur Capital explains why it invested in IBISA, a parametric insurance company. The five entries are product lines the article describes. They are one company’s offerings, presented by its investor. Read the original (Published: 19 Aug 2024).Our reading. The common thread is a measured trigger replacing an assessed claim, applied to farmers, livestock keepers, renewable projects, lenders and storage businesses. In most of these the person exposed to weather is not the one who buys the cover, so distribution through an institution may matter as much as the trigger. These remain examples of an approach, not evidence that buyers are unserved.Browse this collection in the Atlas

Small-ticket weather-index crop insurance Livestock heat-stress coverage Weather-risk cover for renewable generation Climate-risk protection for microfinance lenders Agricultural warehouse rental insurance

Kalaari, Earth Observation report summary

The source. A short public summary page for a Kalaari report on earth observation. The full report is a separate document and was not reviewed. Three entries come from problem examples the summary names; two come from its list of industries served and its value-chain framing. Read the original (Published: 22 Jul 2026).Our reading. The three named problems each imply a different buyer: exploration organisations, insurers and the defence establishment. That is more useful than the sector label, because a founder has to choose one of them. The summary itself does not say who pays or how fast, so the notes stop at the questions.Browse this collection in the Atlas

Earth observation for mineral exploration Earth observation for agricultural insurance Domestic satellite intelligence capabilities Maritime and climate observation services (source only)Satellite sensor-to-decision infrastructure (source only)

Kalaari, 3D Printing in Healthcare summary

The source. A short public summary page for a Kalaari report on 3D printing in healthcare. The full report is a separate document and was not reviewed. The summary discusses fit-to-anatomy devices and mentions further applications briefly. Read the original (Published: 16 Jun 2026).Our reading. Personalised prosthetics and implants are the two entries the summary gives enough context for. In both, printing is one step in a clinical workflow involving scanning, design, surgeons or prosthetists, approvals and follow-up. The summary is silent on regulation and evidence, so the notes treat those as open questions rather than assumptions.Browse this collection in the Atlas

Anatomy-specific prosthetics Scan-based personalized implants Bioprinted tissue development (source only)Tailored drug-delivery fabrication (source only)

Speciale Invest, India's Biotech Inflection Point

The source. A pre-seed investor’s essay arguing that India has three sources of advantage in biotech. Each entry corresponds to one of them. The essay is a thesis about defensibility and does not name buyers. Read the original (Published: 4 Mar 2026).Our reading. Two of the three advantages are about production rather than discovery: lower-cost manufacturing of advanced therapies and an existing industrial fermentation base. The data advantage depends on consent and governance work that the essay does not cover. All three are an investor’s argument, so the notes look for the first customer the essay leaves unnamed.Browse this collection in the Atlas

Indian-population biological datasets and discovery platforms Affordable cell and gene therapy production platforms Fermentation platforms for renewable chemicals and materials

Speciale Invest, Longevity by default

The source. An essay on fragmented health records in India that explains how a portfolio company, eka.care, approaches the problem. One entry is the structural problem; three are approaches described through that company. Read the original (Published: 3 Jun 2026).Our reading. The essay places the gap between national digital health architecture and day-to-day clinical work. That makes adoption by doctors and clinics, not the architecture, the testable question. The company’s approaches are examples to learn from rather than evidence of open space.Browse this collection in the Atlas

Interoperable clinical records across Indian providers Clinical documentation embedded in doctor workflows Health infrastructure APIs for developers and institutions Normalising medical documents into longitudinal histories

Speciale Invest, Why We Invested in Dashamlabs

The source. Speciale Invest’s investment note on Dashamlabs, a maker of silica aerogel insulation. One entry is the manufacturing approach; three are applications the note lists. Read the original (Published: 2025-10-17).Our reading. The India-specific claim is about production: making a high-performance material locally instead of relying on imported technology. The applications differ widely in how buyers qualify suppliers, so the order in which a materials company enters them may matter more than the list itself.Browse this collection in the Atlas

Lower-cost aerogel manufacturing Industrial and pipeline thermal insulation EV battery thermal protection materials Cryogenic and building insulation

Speciale Invest, Atmospheric Arbitrage

The source. An article on Speciale Invest’s portfolio company Uravu Labs, which produces water from air using heat. The three entries are its process, a supply model and a data-centre product. Read the original (Published: 14 Jul 2026).Our reading. The process depends on cheap heat, so the opportunity is defined by sites where waste heat and a water need coincide. Selling water or cooling as a service moves risk onto the supplier, which makes contract terms and financing part of the product. These are one company’s approaches, not proof that the market is open.Browse this collection in the Atlas

Waste-heat-driven atmospheric water harvesting Industrial water supply as a service Coupled data-centre cooling and water production

Reading across collections

This section is Bharat in Beta's reading, not a claim made by any of these investors. Each linked entry keeps its own source, date and review; nothing is merged. When several investors say similar things, that shows where their attention is converging. It does not show that a buyer will pay.

The named bottleneck is production, not discovery

In the sources. Ankur Capital’s commentary names the move from laboratory to commercial production and limited manufacturing infrastructure as constraints. Speciale Invest’s biotech essay locates two of India’s advantages in therapy manufacturing cost and an existing fermentation base. Its Dashamlabs note attributes aerogel’s cost to production methods and imported technology.Our reading. Across three publications from two investors, the India-specific argument is about making things at a cost and scale that work, rather than inventing them. For a founder that points to scale-up services, process work and input supply as starting points that do not require owning a new molecule or material. It is still an investor view, and every one of these businesses must find a paying customer at pilot scale.

Biomanufacturing scale-up infrastructure Affordable cell and gene therapy production platforms Fermentation platforms for renewable chemicals and materials Lower-cost aerogel manufacturing

Satellite data reaches farmers through an institution

In the sources. Kalaari’s summary names limited crop insurance coverage as a problem earth observation could help address. Ankur Capital describes IBISA using environmental data to pay on measured triggers, with products for farmers, livestock keepers and lenders.Our reading. In both, the person exposed to weather is rarely the one who buys the data or the cover. An insurer, lender or platform sits in between, and its processes decide whether the product is used. Trigger design is a broadly portable technique; distribution through Indian insurers, lenders and agricultural networks is the local work.

Earth observation for agricultural insurance Small-ticket weather-index crop insurance Livestock heat-stress coverage Climate-risk protection for microfinance lenders

Public infrastructure sets the terms

In the sources. Speciale Invest’s health essay builds on national digital health architecture. Kalaari’s summary frames domestic satellite capability against reliance on foreign providers. Ankur Capital’s commentary is organised around government missions.Our reading. In these collections, public infrastructure and policy shape what a startup can build and who the early buyer is. That can lower the cost of reaching a market, but it also ties the business to specifications, procurement and priorities it does not control. A founder should test how much of the plan still works if those change.

Interoperable clinical records across Indian providers Health infrastructure APIs for developers and institutions Domestic satellite intelligence capabilities Biological agricultural inputs

Left source-only

9 entries have no reviewed note yet

These entries keep their source summary and link. A note would have needed context the saved source does not provide.

Southeast Asian digital agricultural value chains (Omnivore, Harvest 37). Named only as one of four verticals in a separately published Southeast Asian study that was not reviewed. The newsletter gives no user, workflow or India-specific context to analyse responsibly.
Inclusive agricultural financial services (Omnivore, Harvest 37). Named only as one of four verticals in a separately published Southeast Asian study that was not reviewed. The newsletter gives no user, workflow or India-specific context to analyse responsibly.
Agrifood life-science businesses (Omnivore, Harvest 37). Named only as one of four verticals in a separately published Southeast Asian study that was not reviewed. The newsletter gives no user, workflow or India-specific context to analyse responsibly.
Sustainable consumer brands in Southeast Asia (Omnivore, Harvest 37). Named only as one of four verticals in a separately published Southeast Asian study that was not reviewed. The newsletter gives no user, workflow or India-specific context to analyse responsibly.
Integrated biosurveillance infrastructure (Ankur Capital, India's BioEconomy Roadmap 2035 commentary). The commentary mentions this mission only briefly, grouped with infrastructure and regulatory frameworks. It does not describe a user, buyer or workflow for biosurveillance, so a note would have to invent them.
Maritime and climate observation services (Kalaari, Earth Observation report summary). Maritime and climate appear only in the summary’s list of industries served. Without the full report there is no specific problem or user to review.
Satellite sensor-to-decision infrastructure (Kalaari, Earth Observation report summary). The summary uses the value chain as a framing, not a described problem. A responsible note would need the full report’s detail on where gaps sit along the chain.
Bioprinted tissue development (Kalaari, 3D Printing in Healthcare summary). Bioprinted tissue is mentioned in passing as a potential application. The summary gives no stage, user or constraint, and research-stage medicine is too easy to overstate.
Tailored drug-delivery fabrication (Kalaari, 3D Printing in Healthcare summary). Tailored drug delivery is mentioned in passing as a potential application, without a user, setting or constraint to analyse.